A massive regulatory shift is reshaping American healthcare as the FDA unravels its own safety bans on unproven wellness therapies. Driven directly by Health and Human Services Secretary Robert F. Kennedy Jr. and the rising political pressure of his “Make America Healthy Again” agenda, federal regulators are opening the door for compounding pharmacies to legally manufacture controversial peptides.
The FDA scheduled Pharmacy Compounding Advisory Committee meetings for July 23 and 24, 2026. According to the FDA’s formal announcement to review and ease limits on seven unapproved peptides, regulators will evaluate if compounding pharmacies can mix highly sought-after compounds like BPC-157.
Ahead of these summer hearings, the agency is already moving to temporarily reclassify 12 unapproved peptides out of a restrictive ban list. This directly unwinds a September 2023 policy that categorized 19 peptides as “Category 2” bulk drug substances. That previous ruling explicitly prohibited compounding due to significant safety risks, including potential links to cancer, liver damage, and cardiovascular issues.
Peptides are short chains of amino acids. Approved versions like insulin and GLP-1 weight-loss drugs exist. The specific compounded therapies driving this reversal lack extensive human clinical trials proving safety or efficacy.
Kennedy recently told the Joe Rogan Experience he is a “big fan” of peptides. He admitted personal use. He claimed the FDA “illegally” restricted public access. This regulatory easing aligns with his broader political agenda as federal agency oversight faces intense scrutiny from the MAHA movement.
How the Peptide Reversal Impacts Hims & Hers and the Compounding Market
Telehealth giant Hims & Hers is rapidly positioning itself to capitalize on this regulatory pivot. Hims stock experienced a noticeable boost following Kennedy’s public endorsements of alternative therapies. The company acquired a California-based peptide compounding facility in early 2025.
Legitimizing these previously banned treatments opens a massive new revenue stream for commercial telehealth platforms. The Alliance for Pharmacy Compounding is aggressively lobbying regulators. Industry groups argue patient testimonials should hold weight when formal clinical research is absent.
This marks a profound rollback of American medical regulation. Easing access to unproven compounds based on public demand subverts the 1962 mandate requiring rigorous scientific proof of a drug’s safety before it hits the consumer market.